You are here

Share:

Improved CD22 Binders for Effective Immunotherapy Against Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

Summary
The National Cancer Institute (NCI) seeks licensees for a panel of high affinity antibodies against CD22 to be used in improving cancer immunotherapy and prolonging cancer remission.
NIH Reference Number
E-161-2018
Product Type
Keywords
  • CD22, Chimeric Antigen Receptor, T cell, B cell, CAR, CAR-T, ALL, Acute Lymphoblastic Leukemia, Dimitrov
Collaboration Opportunity
This invention is available for licensing.
Contact
Description of Technology

Targeting the CD22 receptor of B-cells with chimeric antigen receptor (CAR)-T cells has been a promising new therapy to treat B-cell malignancies in clinical trials, inducing remission in 70% of patients with relapsed acute lymphoblastic leukemia (ALL). However, diminished CD22 expression on B-cell surface can lead to relapse and decreased remission duration, which may be prevented through increasing CAR-T affinity towards CD22. 
Researchers at the National Cancer Institute (NCI) developed an affinity-matured monoclonal antibody panel including an anti-CD22 antibody variant, L7, displaying a higher affinity against CD22 than the non-affinity matured versions. The inventors at the NCI developed CAR-T cells incorporating the L7 variable fragment and observed prolonged remission using the L7-CAR-T treatment in combination with Bryostatin1-induced CD22 expression in vivo. The L7 antibody can also be used in other antibody-based therapeutics (such as antibody drug conjugates) against B-cell malignancies.

Potential Commercial Applications
  • Adoptive immunotherapy for relapsed / refractory ALL
  • Antibody drug conjugates against relapsed / refractory ALL
  • Treatment of other B-cell malignancies
Competitive Advantages
  • An established, de-risked target as other anti-CD22 targeted therapies have reached and been evaluated in clinical trials
  • Prolonged remission in ALL mouse models
  • High affinity antibodies against CD22 can be used to develop targeted therapies
Inventor(s)

Dimiter Dimitrov Ph.D., ScD (NCI), Zhongyu Zhu Ph.D. (NCI), Terry Fry MD (NCI), Sneha Ramakrishna MD (NCI)

Development Stage
Publications

Haso W, et al. Anti-CD22–chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia.  [PMID 23243285]

Fry TJ, et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.  [PMID: 29155426]

Ramakrishna S, et al. Modulation of Target Antigen Density Improves CAR T-cell Functionality and Persistence.  [PMID: 31110075]

Patent Status
  • U.S. Provisional: U.S. Provisional Patent Application Number 62/697,185 , Filed 12 Jul 2018
  • PCT: PCT Application Number PCT/US2019/041401 , Filed 11 Jul 2019
Therapeutic Area
Updated
Thursday, July 25, 2019